#Greece #Life Sciences #Venture Capital #Athens #Kos Biotechnology

Major Milestone for Kos Biotechnology Partners

In a significant development for the life sciences investment landscape, Kos Biotechnology Partners, a pioneering investment firm, has recently announced the third closing of its inaugural global life sciences fund, successfully raising $123 million (€106 million). This milestone, announced on June 13, 2026, highlights Kos's commitment to bridging the US biopharma ecosystem with Europe, further establishing its presence in the competitive investment field.

Founded by Dr. Simos Simeonidis and Alex Tzoukas, Kos stands out as the first life sciences-focused investment fund operating from Greece, and it has achieved the largest launch of a venture capital fund in the country’s history. This achievement is not only significant for Kos but also represents one of the largest first-time life sciences VC launches across Europe, positioning Greece as an emerging hub in the biotech sector.

Building a Strong Foundation

The successful fundraising was supported by a diverse group of prominent institutional investors, including the lead investor, Hellenic Development Bank of Investments (HDBI), as well as several global family offices. The fund's strategy revolves around flexibility and adaptability, allowing it to invest across different stages of development, from startups to more established companies preparing for their Series C rounds.

Kos aims to identify and back high-impact investments across three primary life sciences subsectors: biotech and novel therapeutics, pharma services, and tech-enabled technologies. Dr. Simos Simeonidis, the firm’s Co-Founder and Managing Partner, expressed enthusiasm about the growing intersection between novel biological research and advanced computing, emphasizing the opportunities these fields present for addressing complex medical challenges.

A Mission to Transform Healthcare

As stated by Dr. Simeonidis, the mission of Kos is to support exceptional entrepreneurs who are redefining the standards of care. The firm leverages its extensive international network to connect US drug development expertise with highly specialized scientific talent found in Europe. Kos's leadership brings a unique blend of financial acumen from Wall Street and deep scientific knowledge to the table, fostering a robust investment environment within Greece's life sciences sector.

Alex Tzoukas, also a Co-Founder and Managing Partner, noted the importance of their cross-border approach, which underscores the potential of merging US scientific innovation with Europe’s expanding life sciences ecosystem. The fact that they secured $123 million in such a short timeframe serves as validation of their investment thesis and mission.

Investment Strategy and Future Direction

Kos’s investment strategy focuses on three key areas:

• - Biotech/Novel Therapeutics: Investing in pioneering solutions that tackle critical healthcare needs.
• - Pharma Services: Supporting advanced contract research and development platforms aimed at expediting drug discovery processes.
• - Tech-Enabled Technologies: Harnessing computer technology, data infrastructure, and machine learning to reduce risks associated with clinical development.

Even in its early stages, Kos has demonstrated strong operational momentum by completing its initial two investments. This includes leading a financing round for Epikast, a tech-enabled pharma services provider, as well as a strategic investment in a biotechnology firm based in San Francisco, with more investments anticipated later this year.

Conclusion

As Kos Biotechnology Partners continues to grow and attract high-caliber investments, it's clear that their strategic vision, combined with a solid operational foundation, positions them at the forefront of the burgeoning biotech landscape in Greece and Europe. Those interested in the life sciences space should closely watch Kos's trajectory as it strives to transform healthcare through innovative investments and strategic partnerships, ultimately benefiting patients and practitioners alike.